CONVERTIBLE
PROMISSORY NOTE


THIS
NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE AND ANY SHARES OF STOCK ISSUABLE UPON THE CONVERSION HEREOF MAY NOT BE
SOLD, OFFERED FOR SALE, MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT
COVERING THIS NOTE OR SUCH SHARES UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR THE DELIVERY OF AN OPINION OF COUNSEL
THAT SUCH REGISTRATION IS NOT REQUIRED. THIS NOTE IS ALSO SUBJECT TO RESTRICTIONS ON TRANSFER.


REGEN
BIOPHARMA, INC.


	Issue Date: December  15, 2017	 	Principal Amount:


1.     
Terms. For value received, the Regen BioPharma, Inc., a Nevada corporation (the "Company") hereby absolutely and
unconditionally promises to pay to the order of __________________________(the "Lender") ON DEMAND AT ANY TIME AFTER
December 15, 2020 (the "Maturity Date"), the principal amount of Thirty Five thousand dollars ($25,000) and interest
on the whole amount of said principal sum outstanding and remaining from time to time unpaid (the "Note"), commencing
from the date hereof and continuing until payment in full of this Note or conversion as hereinafter provided, at an annual rate
equal to ten percent (10%) simple interest. Interest shall be payable quarterly upon demand or upon conversion pursuant to Section
2 hereunder. Interest shall be computed on the basis of the actual number of days elapsed divided by 365. Principal and interest
shall be payable in lawful money of the United States of America, at the principal place of business of the Lender or at such other
place as the Lender may have designated from time to time in writing to the Company.


2.     
Conversion.


2.1
Conversion Right. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid
principal amount of this Note into fully paid and non-assessable shares of Common Stock, as such Common Stock exists on the Issue
Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed
or reclassified at the conversion price (the "Conversion Price") determined as provided herein (a "Conversion").


The Lender
shall have the right to convert one hundred percent (100%) of the Principal Amount and any accrued interest commencing as of the
date which is the earlier of:


(i) One day subsequent to the execution of an
agreement to a transaction whose completion


would
result in a "Change of Control" of the Company. For purposes of this Note, a Change of Control shall be defined as any
transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of
more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately
preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving
entity following the closing of such transaction.


(ii)
One day subsequent to the execution of an agreement to a transaction whose completion would result in a "Change of Control"
of KCL Therapeutics, Inc. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions,
whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding
stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of
Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of
such transaction.


(iii) One day
subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority
percentage of the Company's outstanding equity securities for a limited period of time contingent on shareholders of the Company
tendering a fixed number of their equity securities ("Tender Offer").


(iv) One day subsequent to the closing of a Transaction
Event:

"Transaction Event" shall mean either of:


(a) The
sale by the Company or by KCL Therapeutics, Inc. of the Company's proprietary NR2F6 intellectual property to an unaffiliated third
party, or,


(b)  
The granting of a license by the Company or by KCL Therapeutics, Inc. to an unaffiliated third party granting that unaffiliated
third party the right to develop and/or commercialize the Company's proprietary NR2F6 intellectual property


(v)       That
date which is twenty four (24) months subsequent to the date of execution of this Note.


The number
of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the principal amount of
this Note to be converted (the "Conversion Amount") by the applicable Conversion Price as defined in this Section 2 then
in effect on the date specified in the notice of conversion, in the form attached hereto as Exhibit A (the "Notice of Conversion"),
delivered to the Company by the Lender on such conversion date (the "Conversion Date").


 


2.2 Conversion Price. The "Conversion
Price" shall be defined as the lower $0.025 per share, or, a 75% discount to the closing price of the Common Stock on the
Over-the-Counter Bulletin Board on the trading day immediately prior to the date that a Notice of Conversion is submitted pursuant
to Section 2.3. or, if the Over-the-Counter Bulletin Board is not the principal trading market for such security, the closing price
of such security on the principal securities exchange or trading market where such security is listed or traded on the trading
day immediately prior to the date that a Notice of Conversion is submitted pursuant to Section 2.3. or, if no closing bid price
of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such
security that are listed in the "pink sheets" by the National Quotation Bureau, Inc. on the trading day immediately prior
to the date that a Notice of Conversion is submitted pursuant to Section 2.3.


2.3 Method of Conversion. Subject to Section
2.1, this Note may be converted by the Lender by submitting to the Company a Notice of Conversion by facsimile, e-mail or other
reasonable means of communication dispatched on the Conversion Date prior to 5:00 p.m., New York, New York time. The Lender shall
not be required to physically surrender this Note to the Company unless the entire unpaid principal amount of this Note is so converted.
The Lender and the Company shall maintain records showing the principal amount so converted and the dates of such conversions so
as not to require physical surrender of this Note upon each such conversion. In the event of any dispute or discrepancy, such records
of the Company shall, prima facie, be controlling and determinative in the absence of manifest error. Notwithstanding the foregoing,
if any portion of this Note is converted as aforesaid, the Lender may not transfer this Note unless the Lender first physically
surrenders this Note to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Lender a new
Note of like tenor, registered as the Lender (upon payment by the Lender of any applicable transfer taxes) may request, representing
in the aggregate the remaining unpaid principal amount of this Note.


Upon
receipt by the Company from the Lender of a facsimile transmission, e-mail, or other reasonable means of communication of a Notice
of Conversion meeting the requirements for conversion, the Company shall issue and deliver or cause to be issued and delivered
to or upon the order of the Lender certificates for the Common Stock issuable upon such conversion within ten (10) business days
after such receipt. Upon receipt by the Company of a Notice of Conversion, the Lender shall be deemed to be the Lender of record
of the Common Stock issuable upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest
on this Note shall be reduced to reflect such conversion. All rights with respect to the portion of this Note being so converted
shall forthwith terminate except the right to receive the Common Stock or other securities as herein provided on such conversion.
In lieu of delivering physical certificates representing the Common Stock issuable upon conversion, provided the Company is participating
in the Depository Trust Company ("DTC") Fast Automated Securities Transfer ("FAST") program, upon request of
the Lender, the Company shall use its best efforts to cause its transfer agent to electronically transmit the Common Stock issuable
upon conversion to the Lender by crediting the account of Lender's Prime Broker with DTC through its Deposit Withdrawal Agent Commission
("DWAC") system.


2.4
Concerning the Shares. The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless
(i) such shares are sold pursuant to an effective registration statement under the Act or (ii) the Company or its transfer agent
shall have been furnished with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions
of counsel in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant
to an exemption from such registration or 


(iii) such
shares are sold or transferred pursuant to Rule 144 under the Act (or a successor rule) ("Rule 144") or (iv) such shares
are transferred to an "affiliate" (as defined in Rule 144) of the Company who agrees to sell or otherwise transfer the
shares only in accordance with this Section 2.5 and who is an Accredited Investor as the term Accredited Investor is defined in
Rule 501 of Regulation D, promulgated under the Act.


Subject
to the removal provisions set forth below, until such time as the shares of Common Stock issuable upon conversion of this Note
have been registered under the Act or otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities
as of a particular date that can then be immediately sold, each certificate for shares of issuable upon conversion of this Note
that has not been so included in an effective registration statement or that has not been sold pursuant to an effective registration
statement or an exemption that permits removal of the legend, shall bear a legend substantially in the following form, as appropriate:


"NEITHER THE ISSUANCE OR SALE OF
THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE
STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE
REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL
SHALL BE SELECTED BY THE LENDER), IN A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT."


The
legend set forth above shall be removed and the Company shall issue to the Lender a new certificate therefore free of any transfer
legend if (i) the Company or its transfer agent shall have received an opinion of counsel, in form, substance and scope
customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Common Stock
may be made without registration under the Act and the shares are so sold or transferred, (ii) such Lender provides the Company
or its transfer agent with reasonable assurances that the Common Stock issuable upon conversion of this Note (to the extent such
securities are deemed to have been acquired on the same date) can be sold pursuant to Rule 144 or (iii) in the case of the Common
Stock issuable upon conversion of this Note, such security is registered for sale by under an effective registration statement
filed under the Act or (iv) otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities as
of a particular date that can then be immediately sold.


2.5 Reverse
Stock Splits. If the number of shares of Common Stock outstanding at any time while this Note is outstanding is decreased by
a combination of the outstanding shares of Common Stock, then, following the record date of such combination, the Conversion Price
shall be appropriately increased so that the number of shares of Common Stock issuable on conversion hereof shall be decreased
in proportion to such decrease in outstanding shares.


2.6 Stock
Dividends and Stock Splits. If the Company, at any time while this Note is outstanding subdivides outstanding shares of Common
Stock into a larger number of shares then the Conversion price shall be multiplied by a fraction of which the numerator shall be
the number of shares of Common Stock (excluding any treasury shares of the Company) outstanding immediately before such event and
of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event


 


3.     
Payment.


 




WIRE INSTRUCTIONS:


 


4.          
Prepayment. Notwithstanding anything to the contrary contained herein, the Company shall
have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding
Note in part or in full, including outstanding principal and accrued interest. Any notice of prepayment hereunder shall be delivered
to the Lender at its registered addresses and shall state that the Company is exercising its right to prepay the Note and the date
of prepayment, which shall be not more than ten (10) Trading Days from the date of the prepayment notice. Upon receipt of a prepayment
notice, Lender shall have the right, but not the obligation, to accelerate the conversion period specified in Section 2.1 and convert
that portion of the outstanding principal balance which is subject to prepayment to Common Shares as provided for in Section 2.


5.     
Warrant Coverage. In the event that that the Company exercises its right to prepay the
note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall
receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the
Note into Common shares of the Company. The warrants shall have a strike price of $0.025 per share. See Exhibit B (incorporated
into this Note) for instructions on completing the Exercise of Warrants document.


6.     
Events of Default.


6.1
The following shall constitute events of default (individually an "Event of Default"):


(a)        
default in the payment, when due or payable, of an obligation to pay interest or principal under this Note, which default is not
cured by payment in full of the amount due within thirty (30) days from the date that the Lender receives notice of the occurrence
of such default;


(b)  
filing of a petition in bankruptcy or the commencement of any proceedings under any bankruptcy laws by or against the Company,
which filing or proceeding, is not dismissed within ninety (90) days after the filing or commencement thereof; or


 


(c) failure of
the Company to comply in any way with the terms, covenants or conditions contained in this Note.


6.2 If
an Event of Default shall occur and be continuing, the Lender may, at its option, declare this Note to be immediately due and payable
without further notice or demand, whereupon this Note shall become immediately due and payable without presentment, demand or protest,
all of which are hereby waived by the Company.


7.   
Transfer of Note. This Note may not be transferred or assigned other than a transfer or assignment to an Affiliate of the Lender.
As used herein, the term "Affiliate" means an entity that directly, or indirectly through one or more intermediaries,
controls, or is controlled by, or is under common control with, the Lender.


8.   
Certain Waivers. The Company hereby expressly and irrevocably waives presentment, demand, protest, notice of protest and any
other formalities of any kind.


9.   
Amendment, Modification or Termination. This Note may only be modified, amended, or terminated
(other than by payment in full) by an agreement in writing signed by the Company and the Lender. No waiver of any term, covenant
or provision of this Note shall be effective unless given in writing by the Lender.


10.    
Governing Law. This Note and the obligations of the Company hereunder shall be governed by and interpreted and determined in
accordance with the laws of the State of California (excluding the laws and rules of law applicable to conflicts or choice of law).


 


IN WITNESS
WHEREOF, this Note has been duly executed on behalf of the undersigned on the day and in the year first above written.


	REGEN BIOPHARMA INC	 	 
	 	 	 
	/s/ David R. Koos 	 	 
	David R. Koos, CEO	 	 
	 	 	 
	12/18/ 2017	 	 


 


	 	1